Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Mar 27;16(1):69.
doi: 10.1186/s12957-018-1368-8.

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Baolin Wu  1 , Jun Zhou  1 , Gonghao Ling  1 , Dongyong Zhu  1 , Qingyun Long  2
Affiliations
Comparative Study

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Baolin Wu et al. World J Surg Oncol. .

Abstract

Background: The present study aimed to evaluate the short-term efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres Beads loaded with doxorubicin (DOX) in the treatment of Chinese patients with hepatocellular carcinoma (HCC) compared to conventional TACE (cTACE).

Methods: A total of 54 patients with HCC treated by TACE from June 2016 to February 2017 were retrospectively analyzed. These included 24 cases in the DEB-TACE group and 30 cases in the cTACE group. The clinical efficacy, tumor recurrence rate, and complications were compared between the two groups. Furthermore, liver function tests and alpha-feto protein levels were compared between the two groups before and at 1 week and 1 month after interventional treatment.

Results: There were no significant differences in baseline characteristics (p > 0.05). Tumor response rates and disease control rates in the DEB-TACE group were significantly higher than those in the cTACE group at 3 and 6 months after treatment (p < 0.05). Recurrence rates at 6 months were significantly higher for cTACE compared to DEB-TACE (43.3 vs. 16.7%; p = 0.036). At 1 month, the AFP level in the DEB-TACE group was significantly lower than that in the cTACE group (p = 0.008). At the end of follow-up, four cases in the DEB-TACE group and two cases in the cTACE group were treated with salvage surgery after downstaging the disease. Liver function of both groups improved at 1 month. However, alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels in the DEB-TACE group were better than those in the cTACE group (p < 0.05). The incidence of DOX-related complications in the DEB-TACE group was significantly lower than in the cTACE group (p < 0.05).

Conclusion: The short-term efficacy of DEB-TACE is better, and the complication rates are lower compared to cTACE in the treatment of Chinese patients with HCC. However, long-term clinical efficacy and survival benefit should be analyzed in future studies.

Keywords: CalliSpheres Beads; Drug-eluting beads; Efficacy; Hepatocellular carcinoma; Safety; Transarterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The institutional review board of the Zhongnan Hospital of Wuhan University approved this retrospective study and waived the requirement for patient informed consent.

Consent for publication

Not applicable

Competing interests

This manuscript contains original material that has not been published or submitted to any other journal. The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Phases of DEB-TACE with CBDOX in a 54-year-old male patient. a–b Plain phase and portal phase of pretreatment CT scan revealed a recurrence lesion located at the right lobe of the liver 11 months after surgical resection. c Angiography during the DEB-TACE procedure revealed a comparatively hypervascular lesion. d An enhanced MRI scan performed at 3 months after treatment showed a complete remission to treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–750. doi: 10.1056/NEJM199903113401001. - DOI - PubMed
    1. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010;255(3):955–965. doi: 10.1148/radiol.10091473. - DOI - PMC - PubMed
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md) 2005;42(5):1208–1236. doi: 10.1002/hep.20933. - DOI - PubMed
    1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752–1763. doi: 10.1053/j.gastro.2008.02.090. - DOI - PubMed
    1. Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep. 2017;19(6):40. doi: 10.1007/s11912-017-0597-2. - DOI - PubMed

Publication types

MeSH terms